NEW BIOMARKERS TO COVER CRITICAL MEDICAL NEEDS IN CANCER
The ONCOCHECK study lasts 24 months from January 2017 to December 2018. The project includes six clinical trials involving children and adults suffering from solid or hematological tumors. Biologic samples from more than 2.000 cancer patients will be obtained to evaluate the role of telomeres in cancer. These studies are being sponsored by Life Length who will carry out the project in partnership with 32 Spanish hospitals.
The variables associated to telomere biology will be measured from biological samples applying Life Length’s technologies: TAT (Telomere Analysis Technology) and Q-TRAP. Telomere analysis will be performed on blood samples from subjects from the ONCOCHECK studies. Previous published data show that telomeres from peripheral blood lymphocytes are a reflection of telomeres from the rest of the body. Additionally, we expect to observe significant changes in telomere-related variables, as cancer patients see their immune system altered and over-activated. Finally, blood represents a great option as sample source as it is easily and quickly obtained by low-invasive techniques.
The six clinical studies involved in ONCOCHECK are:
These six clinical studies include: patient recruiting, blood sampling for telomere analysis and patients’ clinical history data gathering. Participants must be cancer diagnosed patients or people in high risk for cancer.